6.
Smith F, Pierce R, Thisted T, van der Horst E
. Conditionally Active, pH-Sensitive Immunoregulatory Antibodies Targeting VISTA and CTLA-4 Lead an Emerging Class of Cancer Therapeutics. Antibodies (Basel). 2023; 12(3).
PMC: 10525963.
DOI: 10.3390/antib12030055.
View
7.
Sharma P, Siddiqui B, Anandhan S, Yadav S, Subudhi S, Gao J
. The Next Decade of Immune Checkpoint Therapy. Cancer Discov. 2021; 11(4):838-857.
DOI: 10.1158/2159-8290.CD-20-1680.
View
8.
Abdi K, Neves G, Pyun J, Kiziltug E, Ahrens A, Kuo C
. EGFR Signaling Termination via Numb Trafficking in Ependymal Progenitors Controls Postnatal Neurogenic Niche Differentiation. Cell Rep. 2019; 28(8):2012-2022.e4.
PMC: 6768562.
DOI: 10.1016/j.celrep.2019.07.056.
View
9.
Sergent P, Plummer S, Pettus J, Mabaera R, DeLong J, Pechenick D
. Blocking the VISTA pathway enhances disease progression in (NZB × NZW) F1 female mice. Lupus. 2017; 27(2):210-216.
PMC: 5753845.
DOI: 10.1177/0961203317716322.
View
10.
Thakkar D, Paliwal S, Dharmadhikari B, Guan S, Liu L, Kar S
. Rationally targeted anti-VISTA antibody that blockades the C-C' loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner. J Immunother Cancer. 2022; 10(2).
PMC: 8823246.
DOI: 10.1136/jitc-2021-003382.
View
11.
Branon T, Bosch J, Sanchez A, Udeshi N, Svinkina T, Carr S
. Efficient proximity labeling in living cells and organisms with TurboID. Nat Biotechnol. 2018; 36(9):880-887.
PMC: 6126969.
DOI: 10.1038/nbt.4201.
View
12.
Siegal G
. The surprisingly flexible PTB domain. Nat Struct Biol. 1999; 6(1):7-10.
DOI: 10.1038/4873.
View
13.
Liu J, Yuan Y, Chen W, Putra J, Suriawinata A, Schenk A
. Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. Proc Natl Acad Sci U S A. 2015; 112(21):6682-7.
PMC: 4450438.
DOI: 10.1073/pnas.1420370112.
View
14.
Schmid P, Adams S, Rugo H, Schneeweiss A, Barrios C, Iwata H
. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018; 379(22):2108-2121.
DOI: 10.1056/NEJMoa1809615.
View
15.
Kondo Y, Ohno T, Nishii N, Harada K, Yagita H, Azuma M
. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma. Oral Oncol. 2016; 57:54-60.
DOI: 10.1016/j.oraloncology.2016.04.005.
View
16.
Zhang K, Zakeri A, Alban T, Dong J, Ta H, Zalavadia A
. VISTA promotes the metabolism and differentiation of myeloid-derived suppressor cells by STAT3 and polyamine-dependent mechanisms. Cell Rep. 2024; 43(1):113661.
PMC: 10851928.
DOI: 10.1016/j.celrep.2023.113661.
View
17.
Geyer F, Pareja F, Weigelt B, Rakha E, Ellis I, Schnitt S
. The Spectrum of Triple-Negative Breast Disease: High- and Low-Grade Lesions. Am J Pathol. 2017; 187(10):2139-2151.
PMC: 5809519.
DOI: 10.1016/j.ajpath.2017.03.016.
View
18.
Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z
. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102.
PMC: 5570223.
DOI: 10.1093/nar/gkx247.
View
19.
Liu H, Li X, Hu L, Zhu M, He B, Luo L
. A crucial role of the PD-1H coinhibitory receptor in suppressing experimental asthma. Cell Mol Immunol. 2017; 15(9):838-845.
PMC: 6203798.
DOI: 10.1038/cmi.2017.16.
View
20.
Cortes J, Cescon D, Rugo H, Nowecki Z, Im S, Yusof M
. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020; 396(10265):1817-1828.
DOI: 10.1016/S0140-6736(20)32531-9.
View